Axel Merseburger, MD, PhD | Authors

March 23, 2022

Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.

March 14, 2022

Axel Merseburger, MD, PhD, looked back on 2022 ASCO GU and the new data presented for the treatment of prostate cancer.

February 23, 2022

Axel Merseburger, MD, PhD, spoke key results of the PRESIDE trial, which examined continuous enzalutamide to treat patients with metastatic castration-resistant prostate cancer and progressive disease.